Literature DB >> 33806450

Cross-Linking Ligation and Sequencing of Hybrids (qCLASH) Reveals an Unpredicted miRNA Targetome in Melanoma Cells.

Ines Kozar1, Demetra Philippidou1, Christiane Margue1, Lauren A Gay2, Rolf Renne2, Stephanie Kreis1.   

Abstract

MicroRNAs are key post-transcriptional gene regulators often displaying aberrant expression patterns in cancer. As microRNAs are promising disease-associated biomarkers and modulators of responsiveness to anti-cancer therapies, a solid understanding of their targetome is crucial. Despite enormous research efforts, the success rates of available tools to reliably predict microRNAs (miRNA)-target interactions remains limited. To investigate the disease-associated miRNA targetome, we have applied modified cross-linking ligation and sequencing of hybrids (qCLASH) to BRAF-mutant melanoma cells. The resulting RNA-RNA hybrid molecules provide a comprehensive and unbiased snapshot of direct miRNA-target interactions. The regulatory effects on selected miRNA target genes in predicted vs. non-predicted binding regions was validated by miRNA mimic experiments. Most miRNA-target interactions deviate from the central dogma of miRNA targeting up to 60% interactions occur via non-canonical seed pairing with a strong contribution of the 3' miRNA sequence, and over 50% display a clear bias towards the coding sequence of mRNAs. miRNAs targeting the coding sequence can directly reduce gene expression (miR-34a/CD68), while the majority of non-canonical miRNA interactions appear to have roles beyond target gene suppression (miR-100/AXL). Additionally, non-mRNA targets of miRNAs (lncRNAs) whose interactions mainly occur via non-canonical binding were identified in melanoma. This first application of CLASH sequencing to cancer cells identified over 8 K distinct miRNA-target interactions in melanoma cells. Our data highlight the importance non-canonical interactions, revealing further layers of complexity of post-transcriptional gene regulation in melanoma, thus expanding the pool of miRNA-target interactions, which have so far been omitted in the cancer field.

Entities:  

Keywords:  BRAF; melanoma; microRNA; qCLASH; targetome

Year:  2021        PMID: 33806450      PMCID: PMC7961530          DOI: 10.3390/cancers13051096

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.575


  79 in total

Review 1.  MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship.

Authors:  Amy E Pasquinelli
Journal:  Nat Rev Genet       Date:  2012-03-13       Impact factor: 53.242

Review 2.  MicroRNA biogenesis pathways in cancer.

Authors:  Shuibin Lin; Richard I Gregory
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

3.  Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma Cells.

Authors:  Or-Yam Revach; Oded Sandler; Yardena Samuels; Benjamin Geiger
Journal:  Cancer Res       Date:  2019-03-26       Impact factor: 12.701

Review 4.  MDM2 and MDM4: p53 regulators as targets in anticancer therapy.

Authors:  Franck Toledo; Geoffrey M Wahl
Journal:  Int J Biochem Cell Biol       Date:  2007-04-08       Impact factor: 5.085

5.  Predicting effective microRNA target sites in mammalian mRNAs.

Authors:  Vikram Agarwal; George W Bell; Jin-Wu Nam; David P Bartel
Journal:  Elife       Date:  2015-08-12       Impact factor: 8.140

Review 6.  Regulation of microRNA biogenesis and its crosstalk with other cellular pathways.

Authors:  Thomas Treiber; Nora Treiber; Gunter Meister
Journal:  Nat Rev Mol Cell Biol       Date:  2019-01       Impact factor: 94.444

7.  miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.

Authors:  Mitchell S Stark; Vanessa F Bonazzi; Glen M Boyle; Jane M Palmer; Judith Symmons; Catherine M Lanagan; Christopher W Schmidt; Adrian C Herington; Robert Ballotti; Pamela M Pollock; Nicholas K Hayward
Journal:  Oncotarget       Date:  2015-07-10

Review 8.  MicroRNAs in melanoma development and resistance to target therapy.

Authors:  Luigi Fattore; Susan Costantini; Debora Malpicci; Ciro Francesco Ruggiero; Paolo Antonio Ascierto; Carlo M Croce; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2017-03-28

9.  miRNA-target chimeras reveal miRNA 3'-end pairing as a major determinant of Argonaute target specificity.

Authors:  Michael J Moore; Troels K H Scheel; Joseph M Luna; Christopher Y Park; John J Fak; Eiko Nishiuchi; Charles M Rice; Robert B Darnell
Journal:  Nat Commun       Date:  2015-11-25       Impact factor: 14.919

10.  A novel class of microRNA-recognition elements that function only within open reading frames.

Authors:  Kai Zhang; Xiaorong Zhang; Zhiqiang Cai; Jie Zhou; Ran Cao; Ya Zhao; Zonggui Chen; Dehe Wang; Wen Ruan; Qian Zhao; Guangqiao Liu; Yuanchao Xue; Yan Qin; Bing Zhou; Ligang Wu; Timothy Nilsen; Yu Zhou; Xiang-Dong Fu
Journal:  Nat Struct Mol Biol       Date:  2018-10-08       Impact factor: 15.369

View more
  4 in total

1.  A noncanonical microRNA derived from the snaR-A noncoding RNA targets a metastasis inhibitor.

Authors:  Daniel Stribling; Yi Lei; Casey M Guardia; Lu Li; Christopher J Fields; Pawel Nowialis; Rene Opavsky; Rolf Renne; Mingyi Xie
Journal:  RNA       Date:  2021-04-01       Impact factor: 5.636

2.  Sequencing of Argonaute-bound microRNA/mRNA hybrids reveals regulation of the unfolded protein response by microRNA-320a.

Authors:  Christopher J Fields; Lu Li; Nicholas M Hiers; Tianqi Li; Peike Sheng; Taha Huda; Jixiu Shan; Lauren Gay; Tongjun Gu; Jiang Bian; Michael S Kilberg; Rolf Renne; Mingyi Xie
Journal:  PLoS Genet       Date:  2021-12-16       Impact factor: 5.917

Review 3.  DISE/6mer seed toxicity-a powerful anti-cancer mechanism with implications for other diseases.

Authors:  Ashley Haluck-Kangas; Monal Patel; Bidur Paudel; Aparajitha Vaidyanathan; Andrea E Murmann; Marcus E Peter
Journal:  J Exp Clin Cancer Res       Date:  2021-12-10

4.  Modified Cross-Linking, Ligation, and Sequencing of Hybrids (qCLASH) to Identify MicroRNA Targets.

Authors:  Lauren A Gay; Peter C Turner; Rolf Renne
Journal:  Curr Protoc       Date:  2021-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.